Magnitude and time course of platelet inhibition with extended release dipyridamole with or without aspirin in healthy Japanese volunteers

Victor L Serebruany; Alex I Malinin; Dan F Hanley

doi:10.1160/TH07-09-0563

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2008; 99(01): 116-120
DOI: 10.1160/TH07-09-0563

Platelets and Blood Cells

Schattauer GmbH

Magnitude and time course of platelet inhibition with extended release dipyridamole with or without aspirin in healthy Japanese volunteers

The AGgrenox versus Aspirin Therapy Evaluation (AGATE-Japan)

Victor L Serebruany

¹HeartDrug^TM Research Laboratories

²Johns Hopkins University, Baltimore, Maryland, USA

,

Alex I Malinin

¹HeartDrug^TM Research Laboratories

,

Dan F Hanley

²Johns Hopkins University, Baltimore, Maryland, USA

› Author Affiliations

Abstract

Summary

Randomized trials showed greater stroke prevention with extended release dipyridamole in combination with low dose aspirin than with either aspirin or dipyridamole alone. However, most studies with this formulation (Aggrenox^Ⓡ) were carried out in Europe and North America. Considering potential inter-racial differences in drug response, we conducted a small randomized study in healthy Japanese volunteers to compare antiplatelet regimens with regard to the changes in the platelet biomarkers. Thirty healthy volunteers (18–40 years old, 15 male and 15 female) of Japanese descent were randomized to Aggrenox (n=17) or aspirin 81 mg (n=13 volunteers) for 30 days. Platelet function was assessed at baseline, and on days 15, and 30 by conventional aggregometry, whole blood flow cytometry, and cartridge-based analyzer. Both Aggrenox and aspirin provided sustained platelet inhibition at Day 15 and Day 30.Therapy withAggrenox, however, was associated with more prominent and significant inhibition of collagen-induced aggregation (p=0.08, Day 15), as well as prolongation of the closure time (p=0.001, Day 30); diminished expression of platelet endothelial cell adhesion molecule-1 (PECAM-1) (p=0.02, Day 30), glycoprotein IIb (GPIIb) antigen (p=0.001 and 0.024 for Day 15 and Day 30), and GPIIb/IIIa activity by PAC-1 antibody (p = 0.014 and 0.03), CD62 (P-selectin) (p = 0.03 for Day 15 and Day 30), as well as inhibition of protease activated receptors (PAR-1) associated with intact WEDE-15 (p = 0.002 and 0.003) and SPAN-12 (p = 0.002 and 0.04) thrombin receptors when compared with aspirin. The magnitude and durability of platelet response after Aggrenox in healthy Japanese is similar to those effects observed in Caucasians and African- Americans. A larger study to assess drug efficacy and safety in the Japanese post-stroke patients is warranted.

Keywords

Randomized trials - aspirin - Aggrenox^Ⓡ - dipyridamole - platelets - Japanese

Full Text

References

References
1 Muller TH, Su CA, Weisenberger H. et al. Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo. Br J Clin Pharmacol 1990; 30: 179-186.
2 Muller TH. Inhibition of thrombus formation by low-dose acethylsalycilic acid, dipyridamole, and their combination in a model of platelet – vessel wall interaction. Neurology 2001; 57: S8-11.
3 Eldor A, Vlodavsky I, Fuks Z. et al. Different effects of aspirin, dipyridamole and UD-CG 115 on platelet activation in a model of vascular injury: studies with extracellular matrix covered with endothelial cells. Thromb Haemost 1986; 56: 333-339.
4 Serebruany VL, Malinin AI, Sane DC. et al. Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial. Eur J Pharmacol 2004; 499: 315-324.
5 Diener HC, Cunha L, Forbes C. et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13.
6 Diener HC, Bogousslavsky J, Brass LM. et al. and the MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent is- chaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-337.
7 Serebruany VL, Malinin AI, Eisert RM. et al. Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials. Am J Hematol 2004; 75: 40-47.
8 Halkes PH, van Gijn J, Kappelle LJ. the ESPRIT Study Group.. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367: 1665-1673.
9 Albers GW, Amarenco P, Easton JD. et al. Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 483S-512S.
10 Coull BM, Williams LS, Goldstein LB. et al. Joint Stroke Guideline Development Committee of the American Academy of Neurology; American Stroke Association. Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association). Stroke 2002; 33: 1934-1942.
11 Ruggeri ZM. New insights into the mechanisms of platelet adhesion and aggregation. Semin Hemat 1994; 31: 229-239.
12 Mammen EF, Comp PC, Gosselin R. et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998; 24: 195-202.
13 Ault KA. Flow cytometric measurement of platelet function and reticulated platelets. Ann New York Acad Sci 1993; 677: 293-308.
14 Serebruany VL, Gurbel PA. The relations of major platelet receptor expression during myocardial infarction. Monitoring efficacy of GPIIb/IIIa inhibitors by measuring P - selectin? Thromb Haemost 1999; 81: 314-316.
15 Akinboboye OO, Idris O, Chou RL. et al. Absolute quantitation of coronary steal induced by intravenous dipyridamole. J Am Coll Cardiol 2001; 37: 109-116.
16 Eisert WG. Near-field amplification of antithrombotic effects of dipyridamole through vessel wall cells. Neurology 2001; 57: S20-S23.
17 Iuliano L, Pedersen JZ, Rotilio G. et al. A potent chain-breaking antioxidant activity of the cardiovasculardrug dipyridamole. Free Radic Biol Med 1995; 18: 239-247.
18 Selley ML, Czeti AL, McGuiness JA. et al. Dipyridamole inhibits the oxidative modification of low density lipoprotein. Atherosclerosis 1994; 111: 91-97.
19 Neri Serneri GG, Masotti G, Poggesi L. et al. Enhanced prostacyclin production by dipyridamole in man. Eur J Clin Pharmacol 1981; 21: 9-15.
20 Costantini V, Talpacci A, Bastiano ML. et al. Increased prostacyclin production from human veins by dipyridamole: An in vitro and ex vivo study. Biomed Biochim Acta 1990; 49: 263-271.
21 Bult H, Fret HR, Jordaens FH. et al. Dipyridamole potentiates the anti-aggregating and vasodilator activity of nitric oxide. Eur J Pharmacol 1991; 199: 1-8.
22 De La Cruz JP, Blanco E, Sanchez de la, Cuesta F. Effect of dipyridamole and aspirin on the platelet-neutrophil interaction via the nitric oxide pathway. Eur J Pharmacol 2000; 397: 35-41.
23 Singh JP, Rothfuss KJ, Wiernicki TR. et al. Dipyridamole directly inhibits vascular smooth muscle cell profileration in vitro and in vivo: implications in the treatment of restenosis after angioplasty. J Am Coll Cardiol 1994; 23: 665-71.
24 Himmelfarb J, Couper L. Dipyridamole inhibits PDGF- and bFGF-induced vascular smooth muscle cell proliferation. Kidney Int 1997; 52: 1671-1677.
25 Statistics and Information Department. Minister’s Secretariat, Ministry of Health and Welfare. Vital Statistics, 1950-90, Japan [in Japanese].. Tokyo, Japan: Statistics and Information Department, Minister’s Secretariat, Ministry of Health and Welfare; 1950. 1990
26 Kokumin-Iryohi-no-Gaikyo (National Medical Care Expenditure 2003) http://www.mhlw.go.jp/toukei/saikin/hw/k-iryohi/03/index.html. (in Japanese).
27 Kubo M, Kiyohara Y, Kato I. et al. Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. Stroke 2003; 34: 2349-2354.
28 Heart Disease and Stroke Statistics—2007 Update. Circulation 2007; 115: e69-e171.
29 Curb JD, Abbott RD, Rodriguez BL. et al. High density lipoprotein cholesterol and the risk of stroke in elderly men: the Honolulu Heart Program. Am J Epidemio 2004; 160: 150-157.
30 Donovan MD. Sex and racial differences in pharmacological response: effect of route of administration and drug delivery system on pharmacokinetics. J Womens Health (Larchmt) 2005; 14: 30-37.
31 Chen ML. Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 2006; 45: 957-964.
32 Johnson JA. Influence of race or ethnicity on pharmacokinetics of drugs. J Pharm Sci 1997; 86: 1328-1333.
33 Johnson JA. Predictability of the effects of race or ethnicity on pharmacokinetics of drugs. Int J Clin Pharmacol Ther 2000; 38: 53-60.
34 Hu OY, Ding PY, Huang CS. et al. Pharmacokinetics of fosinoprilat in Chinese and whites after intravenous administration. J Clin Pharmacol 1997; 37: 834-840.
35 Jin EZ. A comparison of alpha 1-acid glycoprotein (AAG) concentration and disopyramide binding in Chinese and Japanese. Hokkaido Igaku Zasshi 1999; 74: 279-88.
36 Chen ZM, Jiang LX, Chen YP. et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 160716-160721.